Nanotechnology development and utilization: A primer for diagnostic and interventional radiologists

Radiographics

Volumn 31, Issue 5, 2011, Pages 1449-1462

  Monsky, Wayne L ^a   Vien, Derek S ^a   Link, Daniel P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG CARRIER; NANOPARTICLE;

ANIMAL; ARTICLE; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; ECONOMICS; EDUCATION; FINANCIAL MANAGEMENT; HUMAN; INTERVENTIONAL RADIOLOGY; INTRALESIONAL DRUG ADMINISTRATION; METHODOLOGY; MOLECULAR IMAGING; NANOTECHNOLOGY; NEOPLASM; RADIOLOGY;

ANIMALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FINANCING, ORGANIZED; HUMANS; INJECTIONS, INTRALESIONAL; MOLECULAR IMAGING; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; RADIOLOGY; RADIOLOGY, INTERVENTIONAL;

EID: 80052893546     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.315105238     Document Type: Article

References (75)

1. Ratner M, Ratner D. Size matters. In: Ratner M, Ratner D, eds. Nanotechnology. Upper Saddle River, NJ: Prentice Hall, 2003;11-18.
2. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med 2010;363(25):2434-2443.
3. Power S, Slattery MM, Lee MJ. Nanotechnology and its relationship to interventional radiology. Part I: imaging. Cardiovasc Intervent Radiol 2011;34(2):221-226.
4. Power S, Slattery MM, Lee MJ. Nanotechnology and its relationship to interventional radiology. Part II: drug delivery, thermotherapy, and vascular intervention. Cardiovasc Intervent Radiol 2010 Sep 16. [Epub ahead of print]
5. Goldberg SN, Bonn J, Dodd G, et al. Society of Interventional Radiology Interventional Oncology Task Force: interventional oncology research vision statement and critical assessment of the state of research affairs. J Vasc Interv Radiol 2005;16(10):1287-1294.
6. Drexler KE. Engines of creation. New York, NY: Anchor, 1986.
7. Drexler KE. Nanosystems: molecular machinery, manufacturing, and computation. New York, NY: Wiley Interscience, 1992.
8. Qin LC, Zhao X, Hirahara K, Miyamoto Y, Ando Y, Iijima S. The smallest cardon nanotube. Nature 2000;408(6808):50.
9. Curl RF, Smalley RE. Probing c60. Science 1988;242(4881):1017-1022.
10. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006;23(7):1417-1450.
11. Thrall JH. Nanotechnology and medicine. Radiology 2004;230(2):315-318.
12. Djordjević A, Bogdanović G, Dobrić S. Fullerenes in biomedicine. J BUON 2006;11(4):391-404.
13. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR Jr. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006;7(2):572-579.
14. Aswathy RG, Yoshida Y, Maekawa T, Kumar DS. Near-infrared quantum dots for deep tissue imaging. Anal Bioanal Chem 2010;397(4):1417-1435.
15. Lim EH, Danthi N, Bednarski M, Li KC. A review: integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine 2005;1(2):110-114.
16. Hsu AR, Cai W, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007;48(3):445-454.
17. Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M. Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging 2007;51(2):152-163.
18. Cormode DP, Skajaa T, Fayad ZA, Mulder WJ. Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol 2009;29(7):992-1000.
19. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006;58(14):1471-1504.
20. Sitharaman B, Kissell KR, Hartman KB, et al. Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun (Camb) 2005(31):3915-3917.
21. Shen T, Weissleder R, Papisov M, Bogdanov A Jr, Brady TJ. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med 1993;29(5):599-604.
22. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003;63(18):5838-5843.
23. Michel SC, Keller TM, Fröhlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002;225(2):527-536.
24. Lahaye MJ, Engelen SM, Kessels AG, et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 2008;246(3):804-811.
25. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348(25):2491-2499.
26. van Tilborg GA, Mulder WJ, Deckers N, et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug Chem 2006;17(3):741-749.
27. Harisinghani M. Nanoparticle-enhanced MRI: are we there yet? Lancet Oncol 2008;9(9):814-815.
28. Rabin O, Perez JM, Grimm J, Wojtkiewicz G, Weissleder R, Weissleder R. An x-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 2006;5(2):118-122.
29. Wyss C, Schaefer SC, Juillerat-Jeanneret L, et al. Molecular imaging by micro-CT: specific E-selectin imaging. Eur Radiol 2009;19(10):2487-2494.
30. Villanueva FS, Jankowski RJ, Klibanov S, et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation 1998;98(1):1-5.
31. Gao ZG, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release 2005;102(1):203-222.
32. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107(19):2453-2458.
33. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005;96(3):327-336.
34. Coto-García AM, Sotelo-González E, Fernández-Argüelles MT, Pereiro R, Costa-Fernández JM, Sanz-Medel A. Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics. Anal Bioanal Chem 2011;399(1):29-42.
35. Sheth RA, Mahmood U. Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2010;299(4): G807-G820.
36. Schellenberger EA, Högemann DD, Josephson L, Weissleder R. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Acad Radiol 2002;9(Suppl 2):S310-S311.
37. Marsh JN, Senpan A, Hu G, et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond) 2007;2(4):533-543.
38. Culp WC, Porter TR, McCowan TC, et al. Microbubble-augmented ultrasound declotting of thrombosed arteriovenous dialysis grafts in dogs. J Vasc Interv Radiol 2003;14(3):343-347.
39. Tiukinhoy-Laing SD, Buchanan K, Parikh D, et al. Fibrin targeting of tissue plasminogen activator-loaded echogenic liposomes. J Drug Target 2007;15(2):109-114.
40. Kong DF, Goldschmidt-Clermont PJ. Tiny solutions for giant cardiac problems. Trends Cardiovasc Med 2005;15(6):207-211.
41. Nakano K, Egashira K, Masuda S, et al. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv 2009;2(4):277-283.
42. Bhargava B, Reddy NK, Karthikeyan G, et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter Cardiovasc Interv 2006;67(5):698-702.
43. Guzman LA, Labhasetwar V, Song C, et al. Local intraluminal infusion of biodegradable polymeric nanoparticles: a novel approach for prolonged drug delivery after balloon angioplasty. Circulation 1996;94(6):1441-1448.
44. Ellis-Behnke RG, Liang YX, Tay DK, et al. Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2006;2(4):207-215.
45. Yang X. Interventional molecular imaging. Radiology 2010;254(3):651-654.
46. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004;11(9):996-1004.
47. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008;26(1):57-64.
48. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group: phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20(3):449-453.
49. Ahmed M, Monsky WE, Girnun G, et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003;63(19):6327-6333.
50. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 2005;16(10):1365-1371.
51. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998;95(8):4607-4612.
52. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 2008;26(11):612-621.
53. Kalambur VS, Longmire EK, Bischof JC. Cellular level loading and heating of superparamagnetic iron oxide nanoparticles. Langmuir 2007;23(24):12329-12336.
54. Gannon CJ, Cherukuri P, Yakobson BI, et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007;110(12):2654-2665.
55. Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE Proc Nanobiotechnol 2005;152(1):33-39.
56. Johannsen M, Gneveckow U, Thiesen B, et al. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 2007;52(6):1653-1661.
57. Takamatsu S, Matsui O, Gabata T, et al. Selective induction hyperthermia following transcatheter arterial embolization with a mixture of nano-sized magnetic particles (ferucarbotran) and embolic materials: feasibility study in rabbits. Radiat Med 2008;26(4):179-187.
58. Huang X, Qian W, El-Sayed IH, El-Sayed MA. The potential use of the enhanced nonlinear properties of gold nanospheres in photothermal cancer therapy. Lasers Surg Med 2007;39(9):747-753.
59. Borm PJ, Robbins D, Haubold S, et al. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol 2006;3:11.
60. Curtis J, Greenberg M, Kester J, Phillips S, Krieger G. Nanotechnology and nanotoxicology: a primer for clinicians. Toxicol Rev 2006;25(4):245-260.
61. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008;3(2):133-149.
62. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65(1-2):271-284.
63. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-263.
64. Monsky WL, Mouta Carreira C, Tsuzuki Y, Gohongi T, Fukumura D, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002;8(4):1008-1013.
65. Al-Abd AM, Hong KY, Song SC, Kuh HJ. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 2010;142(1):101-107.
66. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5(2):79-88.
67. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010;52(3):380-388.
68. Seibel RM, Melzer A, Schmidt A, Plabetamann J. Computed tomography-and magnetic resonance imaging: guided microtherapy. Semin Laparosc Surg 1997;4(2):61-73.
69. Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol 2010 Nov 8. [Epub ahead of print]
70. Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008;60(10):1137-1152.
71. Li X, Li R, Qian X, et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm 2008;70(3):726-734.
72. Lesinski GB, Sharma S, Varker KA, Sinha P, Ferrari M, Carson WE 3rd. Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed Microdevices 2005;7(1):71-79.
73. Damascelli B, Cantù G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal-preliminary evidence of clinical activity. Cancer 2001;92(10):2592-2602.
74. Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 2007;99(14):1095-1106.
75. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.